Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer
Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether OSI-211 (Liposomal Lurtotecan) is an
effective and safe treatment for patients with recurrent small cell lung cancer.